is bpc 157 subcutaneous or intramuscular Dosage: A Doctor's Evidence-Based Guide Where to inject BPC 157

This product is intended for intravenous (IV) use by a healthcare professional

dietary structure becomes critical to maintain energy balance without the incretin-mediated satiety signal

WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use

Researchers conclude that larger, well-designed clinical trials are needed to evaluate its safety, efficacy, and potential adverse effects before clinical use can be recommended